# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ella Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML029-SYN
- Date: 2026-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odessa Whitlow, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for new patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk. **S**

## Objective

Hemoglobin A1c: 8.6% (high); Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Creatinine: 0.92 mg/dL; eGFR: 67 mL/min/1.73 m²; Glucose: 168 mg/dL (high); Urine albumin-creatinine ratio: 18 mg/g; Total cholesterol: 164 mg/dL; LDL cholesterol: 92 mg/dL; HDL cholesterol: 44 mg/dL (low); Triglycerides: 140 mg/dL; ALT: 22 U/L; AST: 24 U/L; Hemoglobin: 12.4 g/dL; Vitamin B12: 386 pg/mL; Ankle-brachial index, right: 0.62 (low); Ankle-brachial index, left: 0.74 (low); Toe-brachial index, right: 0.46 (low); Toe-brachial index, left: 0.55 (low); Best-corrected visual acuity, right eye (ETDRS letters): 64 (low); Best-corrected visual acuity, left eye (ETDRS letters): 81. All results are synthetic.

BP 126/70 mmHg; pulse 62 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 84 kg; BMI 30.9 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications; Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems; Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Stopped: Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals **S**
- Stopped: Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime **S**
- Started: Insulin glargine 100 units/mL pen, 24 units under the skin each morning **S**
- Stopped: Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Started: Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Continued without change: Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Continued without change: Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Started: Empagliflozin 10 mg oral tablet, one tablet by mouth each morning **S**
- Started: Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose **S**

## Plan

- Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color change. Guideline: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Vascular surgery consultation for claudication with an ankle-brachial index of 0.62: arterial duplex, supervised exercise therapy, and whether and when revascularization should be considered, before any loss of tissue. Guideline: The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explained. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%). Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHg. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materials. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformin. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touring. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
